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Recent studies suggest an association between the Interferon Inducible Transmembrane 3
(IFITM3) rs12252 variant and the course of influenza infection. However, it is not clear
whether the reported association relates to influenza infection severity. The aim of this
study was to estimate the hospitalization risk associated with this variant in Influenza Like Ill-
ness (ILI) patients during the H1N1 pandemic influenza.
Methods
A case-control genetic association study was performed, using nasopharyngeal/oropharyn-
geal swabs collected during the H1N1 pandemic influenza. Laboratory diagnosis of influenza
infection was performed by RT-PCR, the IFITM3 rs12252 was genotyped by RFLP and tested
for association with hospitalization. Conditional logistic regression was performed to calculate
the confounder-adjusted odds ratio of hospitalization associated with IFITM3 rs12252.
Results
We selected 312 ILI cases and 624matched non-hospitalized controls. Within ILI Influenza
A(H1N1)pdm09 positive patients, no statistical significant association was found between
the variant and the hospitalization risk (Adjusted OR: 0.73 (95%CI: 0.33–1.50)). Regarding
ILI Influenza A(H1N1)pdm09 negative patients, CT/CC genotype carriers had a higher risk of
being hospitalized than patients with TT genotype (Adjusted OR: 2.54 (95%CI: 1.54–4.19)).
Conclusions
The IFITM3 rs12252 variant was associated with respiratory infection hospitalization but not
specifically in patients infected with Influenza A(H1N1)pdm09.
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Introduction
Influenza is a contagious and debilitating disease of the respiratory tract that can lead to hospi-
talization and even death, remaining a public health threat. In April 2009, an outbreak of influ-
enza A(H1N1)pdm09 infection was detected in Mexico, with subsequent cases observed in
many other countries, including Portugal. It has spread quickly throughout the world and
caused at least 15000 deaths in less than a year [1]. Unlike the disease pattern observed during
epidemics of seasonal influenza, many of the severe cases of influenza A(H1N1)pdm09 virus
infection were observed in healthy young people, with approximately 90% of all deaths due to
influenza occurring in those younger than 65 years [2]. Most people infected with influenza A
(H1N1)pdm09 virus experienced mild disease, with upper respiratory illness similar to sea-
sonal influenza virus infection. In contrast, gastrointestinal symptoms occurred more fre-
quently in patients infected with pandemic influenza virus than in those with seasonal
influenza [3]. According to the Portuguese Influenza Surveillance Program (NISP), 64% of the
laboratory-confirmed cases for the influenza A(H1N1)pdm09 virus were detected in the age
group of 5–14 years old. A total of 1436 hospitalizations were reported, and the estimated mor-
tality rate was 1.17 per 100000 inhabitants, corresponding to 124 laboratory confirmed influ-
enza deaths [4].
It is commonly accepted that the severity of influenza A(H1N1)pdm09 infection results
from a complex interplay between host and pathogen factors but there are many gaps in the
basic understanding of what influences illness severity mainly among people without known
comorbidities. While some individuals resist infection or recover quickly, others experience
severe disease associated with the infection. Intensive research has been performed on the viru-
lence of the virus including its genomic variability but very little is known about the host
genetic background influence in the influenza outcome, despite its crucial impact on the
immune response and the course of infection [5]. Consequently, in 2009, the World Health
Organization identified studies of the host genetic factors’ role on susceptibility to severe influ-
enza as a priority [6].
Although characteristics such as age, comorbidities, degree of pre-existing immunity,
immunosupression, pregnancy and smoking influence the acquisition, progression and resolu-
tion of influenza infections, genetic variants found in human populations affect the specificity
of virus binding and subsequent effectiveness of the immune response [7]. Their importance in
humans has already been shown for several bacterial and viral pathogens [8] and it is currently
known that infectious disease lethality has a heritable component [9]. In addition, animal mod-
els seem to support the biologic plausibility of a genetic susceptibility to influenza A virus,
given that some mouse strains are more susceptible to influenza virus infection and severity,
independently of virus subtype, suggesting common infection pathways [10].
It has been shown that an interferon inducible transmembrane 3 protein (IFITM3), which
acts as a viral restriction factor that mediates cellular resistance to several viruses by blocking
early stages of viral replication, profoundly alters the course of influenza virus infection in a
knockout mouse model. Mice lacking a functional Ifitm3 gene developed severe viral pneumo-
nia when challenged with normally low pathogenic viruses, and protection was re-established
with reintroduction of Ifitm3. In humans, an overrepresentation of individuals with the
IFITM3 rs12252 variant (C allele) that alters a splice acceptor site was found in European
patients who required hospitalization as a result of influenza infection [11].
Recent studies suggest a close association between the IFITM3 rs12252 variant (C allele)
and influenza severity infection. [12,13]. More specifically a meta-analysis which included the
previously referred studies suggests a significant association between the IFITM3 rs12252 vari-
ant (C allele) and severe influenza susceptibility, but not in mild influenza subjects, both in UK
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Caucasians and Han Chinese populations, concluding that the C allele constitutes a risk factor
for more severe influenza infection cases [14].
Considering the wider confidence intervals, the small samples sizes and the heterogeneity in
the inclusion criteria of the previous studies, the main objective of the present study was to esti-
mate the association between the IFITM3 rs12252 variant (C allele) and the risk of hospitaliza-
tion due to respiratory illness in Portuguese patients with influenza A(H1N1)pdm09 infection
using an appropriately designed epidemiological study.
Methods
Study design and participants
A case-control genetic association study, comparing the frequency of IFITM3 rs12252 variant
between hospitalized influenza-like illness (ILI) patients (cases) and non hospitalized ILI
patients (controls) was performed. Biological samples from cases and controls consisted on the
nasopharyngeal/oropharyngeal swabs received by the Portuguese National Influenza Reference
Laboratory, at the National Health Institute Doctor Ricardo Jorge (INSA) for diagnostic pur-
poses during the H1N1 pandemic, from the Portuguese Laboratory Network for the Diagnosis
of Influenza Infection between September 2009 and February 2010 [15].
INSA coordinated this network that was responsible for carrying out the laboratory diagno-
sis of influenza A(H1N1)pdm09 infection requested by the National Health Service during the
pandemic (H1N1)2009. This network received swabs from ILI patients identified by primary
healthcare units and hospitals. All information collected regarding clinical and epidemiological
information, such as patients’ demographic data, signs and symptoms and underlying condi-
tions and laboratory results were stored in a national common database. A total of 62089 ILI
cases were reported to the laboratory network during the H1N1 pandemic. From these 25985
were laboratory-confirmed influenza cases, over 99% of which were associated with the new
pandemic strain A(H1N1)[15]. At INSA 16376 samples for Influenza diagnosis were received.
Of those, 7780 influenza A(H1N1)pdm09 positive cases were identified.
An ILI positive patient was defined as a patient presenting signs and symptoms complying
to the European ILI case definition [16], who was swabbed and tested positive for influenza A
(H1N1)pdm09 using real-time polymerase chain reaction (RT-PCR) [17]. ILI negative patients
were ILI patients who were swabbed and tested negative for the Influenza A(H1N1)pdm09
virus. ILI patients tested negative for Influenza A(H1N1)pdm09 virus also tested negative for
the Influenza A and B virus subtypes.
All included patients were selected from the INSA cases, whose tests for Influenza diagnosis
were performed at National Influenza Reference Laboratory (INSA). The following exclusion
criteria were used to perform the selection: (1) patients over 65 years old; (2) immunodepressed
or transplanted patients (3) patients with chronic diseases (diabetes, lung, kidney, cardiovascu-
lar, liver, neurological, immunologic and oncologic diseases); (4) pregnant women; (5) notifica-
tion data before the mitigation phase (01-09-2009); (6) patients for whom the time lapse
between the symptoms onset and the sample collection was over 7 days, to avoid misclassifica-
tion due to low viral load of the sample collected; (7) samples with unavailable information
about hospitalization; (8) samples with unavailable laboratorial result for A(H1N1)pdm09
virus; (9) samples stored outside of the National Health Institute Doutor Ricardo Jorge.
After the exclusion criteria application, 312 hospitalized patients were identified. These
cases were stratified in two groups: hospitalized Influenza A(H1N1)pdm09 positive cases
(n = 108) and hospitalized Influenza A(H1N1)pdm09 negative cases (n = 204). Since the risk
of developing Influenza varies with time and to assure that the selected control group was at
similar risk of developing the health outcome of interest, for each case in the group of
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hospitalized cases, 2 non-hospitalized controls matched for the week of onset of symptoms
were selected from the Portuguese Laboratory Network database (Fig 1). Hospitalization was
used as a measure of disease severity. In this context, it was defined as a hospital admission due
to ILI complications with a concomitant hospital stay for more than twenty-four hours. The
study protocol was approved by the Ethics Committee of the National Health Institute Doutor
Ricardo Jorge. Since this study used irreversibly anonymized samples from the NPIS, obtaining
informed consent from the participants was impossible and therefore the study was authorized
by the Ethics Committee of the National Health Institute Doutor Ricardo Jorge without
informed consent by the participants.
Laboratory diagnosis
For laboratory diagnosis and further virological characterization, the nasopharyngeal/oropha-
ryngeal swabs were collected into a suitable transport medium for preservation of virus, molec-
ular diagnostic and virus culture. Real-time reverse transcriptase PCR methodologies and
platforms were used for laboratory diagnosis of influenza infection [17]. Additional diagnoses,
viral isolation, antigenic and genetic characterization of viral isolates were performed according
to the procedures previously described [15]. During the 2009/10 influenza season, the labora-
tory network just carry out the laboratory diagnosis of influenza A(H1N1)pdm09 infection
requested by the National Health Service and the samples were only tested for the influenza A
(H1N1)pdm09, influenza A(H1), influenza A(H3) and influenza B virus.
Genotyping
Genomic DNA was extracted from the nasopharyngeal/oropharyngeal swabs using an auto-
matic system (MagNA Pure LC—Roche) with the MagNA Pure LC Total Nucleic Acid Isola-
tion Kit. The rs12252 SNP in the IFITM3 gene was genotyped by restriction fragment length
polymorphism (RFLP) using the following forward and reverse primers: TGAGGGTTATGGGA
GATGGGGT (F) and GGAGAGGAGATGGTGAGGGGA (R) in standard PCR conditions. The
restriction enzymeMscI was used to cut the PCR product in the presence of the wild type T
allele and the originated fragments were visualized on a 2% agarose gel.
Fig 1. Schematic representation of the sampling process.
doi:10.1371/journal.pone.0158181.g001
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Statistical analysis
Statistical analysis was performed using the R program [18]. P-values<0.05 were considered to
be statistically significant. The T-test and the Wilcoxon test were used to access differences of
quantitative variables according to their adherence to the normal distribution. Proportions
were compared using the Pearson's chi-squared test.
Regarding age and sex, the National Hospitalization Discharge (NHD) database was used to
assess if the sample of influenza positive hospitalized cases analyzed in the present study was a
representative of the total influenza (International Codifications of Diseases code 487.0) hospi-
talized patients in the NHS, during the same period of time and excluding patients over 65
years, with chronic diseases and pregnant women. Allelic and genotypes frequencies were
obtained by direct count and were tested for the Hardy-Weinberg Equilibrium, using the
Hardy Weinberg R package [19]. To perform the case-control association analysis, hospitalized
patients were considered the cases and non-hospitalized patients were considered the controls.
The analysis was stratified by ILI A(H1N1)pdm09 positive and negative patients. To estimate
the Adjusted Odds-Ratio, we used Conditional Logistic Regression for matched Pairs Data
including the potential confounding effect of age and gender variables.
Results
From the 936 patients selected, 909 had sufficient available frozen swabs for DNA extraction.
We successfully genotyped 792 samples: 268 from ILI A(H1N1)pdm09 positives patients (84
hospitalized cases and 184 non-hospitalized controls) and 524 from ILI A(H1N1)pdm09 nega-
tives patients (173 hospitalized cases and 351 non-hospitalized controls) corresponding to an
overall success rate of 87% (95% CI: 84.8%–89.2%) that was similar in all the 4 groups of
patients (p = 0.998) (S1 Table).
No significant differences were found regarding the age (p = 0.382) and sex (p = 0.468) dis-
tributions between cases and controls among ILI A(H1N1)pdm09 positive patients and ILI A
(H1N1)pdm09 negative patients (Table 1). No significant differences were found between the
analysed influenza positive hospitalized cases and influenza diagnosed hospitalized patients
present in the NHD database, regarding age (p = 0.320) and sex (p = 0.133) (S2 Table).
Concerning IFITM3 rs12252 variant characterization (Table 2), 3 patients carrying the CC
genotype were detected (2 were ILI A(H1N1)pdm09 positive hospitalized patients and 1 was a
ILI A(H1N1)pdm09 negative non-hospitalized patient).
Regarding A(H1N1)pdm09 infected patients, 10.7% (95% CI: 4.1–17.3) of the hospitalized
cases and 17.4% (95% CI:11.9–22.9) of the non-hospitalized controls had the CT genotype.
Table 1. Patients characterization regarding age and gender variables.
ILI A(H1N1)pdm09 positive patients ILI A(H1N1)pdm09 negative patients
Hospitalized (cases) Non-hospitalized (controls) p Hospitalized (cases) Non-hospitalized (controls) p
Age (years)
Mean ± sd 16.6 ± 17.6 14.0 ± 12.4 0.8151 15.7 ± 20.2 13.5 ± 16.1 0.3821
Median (range) 10 (0–60) 9 (0–54) 4 (0–64) 6 (0–62)
Gender
% of women 40.5 46.2 0.3822 43.9 47.3 0.4682
(95% CI) (30.0–51.0) (39.0–53.4) (36.5–51.3) (42.1–52.5)
1 p-values were obtained by the Wilcoxon test.
2 p-values were obtained by the Pearson's chi-squared test.
(CI, Conﬁdence interval; p, p-value; sd, standard deviation).
doi:10.1371/journal.pone.0158181.t001
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The hospitalized A(H1N1)pdm09 infected cases had a C allele frequency of 7.7% (95% CI: 3.6–
11.8) while the non-hospitalized controls had a C allele frequency of 8.7% (95% CI: 5.8–11.6).
In the A(H1N1)pdm09 negative patients, 22.5% (95% CI:16.3–28.8) of the hospitalized cases
and 10.8% (95% CI: 7.6–14.1) of the non-hospitalized controls carried the CT genotype. The
hospitalized cases have a C allele frequency of 11.3% (95% CI: 8.0–14.6) while the non-hospi-
talized controls presented a C allele frequency of 5.7% (95% CI: 2.2–9.2) (Table 2).
To assess if there is a higher risk of hospitalization for patients who carry the C allele both in
the presence and absence of the A(H1N1)pdm09 virus infection, we performed a stratified
analysis assuming a dominant model, as presented in Table 2. In the presence of A(H1N1)
pdm09 virus infection, we observed that there is not a higher risk of being hospitalized for
patients with the CT/CC genotype compared to the TT genotype (Adjusted Odds Ratio: 0.73
(95% CI: 0.33–1.50). However, when we use the same approach to assess if there is a higher
risk of being hospitalized for the C allele carriers in patients negative for A(H1N1)pdm09 virus
infection we found that the risk of being hospitalized among the CT/CC genotype carriers is
significantly higher than the risk of being hospitalized in the TT genotype carriers (Adjusted
Odds Ratio: 2.54 (95% CI: 1.54–4.19)).
Discussion
In order to measure the association between the IFITM3 rs12252 variant and influenza A(H1N1)
pdm09 severity infection among ILI patients without reported comorbilities, we have designed a
specific case-control study, in the H1N1 pandemic scenario. Our results show that the IFITM3
rs12252 variant was associated with respiratory disease hospitalizations but not in the ILI
patients with a laboratory confirmed Influenza A(H1N1)pdm09 infection. On the other hand,
Table 2. IFITM3 rs12252 genotypic and allelic frequencies among the four groups of patients and its association with hospitalization, assuming a
dominant model.

















n 84 184 173 351
Genotypes
TT (%) 73 (86.9) 152 (82.6) 134 (77.5) 312 (88.9)
CT (%) 9 (10.7) 32 (17.4) 39 (22.5) 38 (10.8)
CC (%) 2 (2.4) 0 (0) 0 (0) 1 (0.28)
Alleles
C (%) 13 (7.7) 32 (8.7) 39 (11.3) 40 (5.7)
T (%) 155 (92.3) 336 (91.3) 207 (92.3) 662 (94.3)
Dominant
model1
CT/CC (%) 11 (13.1) 32 (17.4) 39 (22.5) 39 (11.1)
vs
TT (%) 73 (86.9) 152 (82.6) 134 (77.5) 312 (88.9)






p value 0.376 0.404 <0.001 <0.001
1 Other genetic models were not considered due the low frequency of CC genotype and the existence of zero patients with CC genotypes in 2 groups.
2Adjustment for age and gender by logistic regression.
doi:10.1371/journal.pone.0158181.t002
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we observed that the risk of being hospitalized for the CT/CC genotype was 2.54 fold when com-
pared to the TT genotype in ILI patients negative for influenza A(H1N1)pdm09 infection.
Given these results, we hypothesize that this variant is involved in the ILI symptoms severity
associated with other respiratory infections. During the H1N1 pandemic influenza season, the
Portuguese Laboratory Network just carried out the influenza virus detection (influenza A
(H1N1)pdm09, influenza A(H1) seasonal, influenza A(H3) and influenza B virus), therefore
we must consider the hypothesis of the presence of other infectious agents associated with
respiratory disease (adenovirus, coronavirus, rhinovirus, respiratory syncytial virus, metapneu-
movirus, parainfluenza virus,Haemophilus influenzae,Mycoplasma pneumoniae, Streptococcus
pneumoniae and other less frequent respiratory agents) in the Influenza negative samples that
could explain our results. In addition, some studies show that IFITM3 is also important in the
mediation of other virus infections such as West Nile Virus and Dengue Virus [20] and this
hypothesis could justify the higher percentage of C allele carriers in the ILI hospitalized Influ-
enza negative cases. The future detection of other respiratory virus in the analyzed samples
would be important to clarify our results.
When comparing our work with the study previously published by Everit el al (2012) [11]
on this SNP regarding European patients, we found a similar percentage of C allele carriers
among the influenza hospitalized positive cases (13.2% versus 13.1%). However, the compari-
son group were not ILI non hospitalized Influenza A(H1N1)pdm09 positive patients, meaning
that they did not test the hypothesis that the IFITM3 rs12252 variant was involved in the sever-
ity of the Influenza infection. More specifically, when comparing the general population with-
out infection (European 1000 genomes) with the ILI hospitalized influenza positive patients
they are evaluating both infection susceptibility and severity without the ability to distinguish
each effect.
The percentage of the C allele carriers in the ILI non-hospitalized Influenza A(H1N1)
pdm09 negative controls is the closest to the general population (European 1000 genomes), as
expected (Fig 2).
Our results must be interpreted taking into account some limitations that are specific of the
study design. The case definition (“hospitalization”) used to measure disease severity might not
be considered as the best measure in a pandemic scenario given that less severe cases were
likely to be hospitalized due to the initial pandemic alert, reducing the effect of IFITM3
rs12252 on the risk of severity (hospitalization). However, we have reduced this bias by exclud-
ing patients with disease onset reported in the contention phase when health authorities had
the indication to hospitalise all influenza A(H1N1)pdm09 cases. In addition, the hospitaliza-
tion criteria that were used in the different health units might not be uniform and could be dif-
ferent from influenza A(H1N1)pdm09 positive and negative cases given the pandemic alert
and the indications of the health authorities This differential criterion for hospitalization could
explain the presence of the IFITM3 rs12252 association in the negative influenza patients and
the absence in the positive influenza patients. The extent of this bias could not be evaluated
with the available data. On the other hand, we only performed the confounding adjustment for
age and sex variables in the logistic regression analysis, but the reduction of possible confound-
ing bias were also achieved by the exclusion criteria used in the patients selection, excluding
patients with known risk factors for influenza infection complication. Regarding the possible
selection bias, we were only able to evaluate the representativeness of the influenza hospitalized
patients with less 65 years of age without known co morbidities, the patients recorded in the
NHD during H1N1 pandemic were not statistical different from the ones included in the study
regarding age and sex variables.
Due the low frequency of the IFITM3 rs12252 observed in the Portuguese population and
also in the European population (3%), a large number of cases would be needed to better define
IFITM3 and Influenza Infection Severity
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this association in our population. In the future, it will be important to perform an integrative
approach to clarify why some healthy individuals resist infection or recover quickly, others
experience severe disease associated with the influenza infection. It could be done by consider-
ing not only the virus-host genome interactions but also immunity, vaccination, weather con-
ditions and other environmental factors that could help to clarify the present results.
Moreover, early screening for the host genetic background could be a promising strategy to
identify potential therapeutic targets and might help to evaluate and predict the severity of dis-
ease thereby providing critical information for decision making during treatment [21].
In conclusion, this study showed that the IFITM3 rs12252 variant was associated with the
hospitalization risk in the ILI hospitalized Influenza A(H1N1)pdm09 negative patients. How-
ever, the same association was not found in the ILI hospitalized Influenza A(H1N1)pdm09
positive cases and we cannot confirm that this variant is involved in the ILI symptoms severity
associated with Influenza A(H1N1)pdm09 infection and the absence of the effect in this group
could be due to bias associated with hospitalization criteria during the pandemic.
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